Orange Book product · Generic (ANDA)
MOMETASONE FUROATE
MOMETASONE FUROATE
At a glance
Jun 14, 2023
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jun 14, 2023
3 yr 1 mo ago
Today
Pharmaceutical detail
Active ingredient
MOMETASONE FUROATE
Strength
0.05MG/SPRAY
Dosage form
SPRAY, METERED
Route
NASAL
TE code
Not listed
Application
ANDA 217460
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of MOMETASONE FUROATE
- 2022NASONEX 24HR ALLERGYBrand (NDA)
NDA 215712 · PERRIGO PHARMA INTL
- 2019ASMANEX HFABrand (NDA)
NDA 205641 · ORGANON LLC
- 2017SINUVABrand (NDA)
NDA 209310 · INTERSECT ENT INC
- 2008ASMANEX TWISTHALERBrand (NDA)
NDA 021067 · ORGANON LLC
- 1997NASONEXBrand (NDA)
NDA 020762 · ORGANON LLC
- 1989ELOCONBrand (NDA)
NDA 019796 · ORGANON
- 1987ELOCONBrand (NDA)
NDA 019625 · ORGANON
- 1987ELOCONBrand (NDA)
NDA 019543 · ORGANON
- 2025MOMETASONE FUROATEGeneric (ANDA)
ANDA 211706 · NASPRESS
- 2024MOMETASONE FUROATEGeneric (ANDA)
ANDA 217498 · AUROBINDO PHARMA
- 2024MOMETASONE FUROATEGeneric (ANDA)
ANDA 217438 · APOTEX
- 2024MOMETASONE FUROATEGeneric (ANDA)
ANDA 215878 · AUROBINDO PHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
